8-K: Kyverna Bolsters Leadership, Funds CAR T Pipeline into 2028

Kyverna Therapeutics announced a corporate update, outlining 2026 strategic priorities, appointing Christi Shaw as Executive Chairperson, and reporting preliminary year-end 2025 financials.

Summary

• Kyverna Therapeutics provided a corporate update and outlined its strategic priorities for 2026.
• Christi Shaw, a current Board member, was appointed Executive Chairperson of the Board, effective January 12, 2026. Ian Clark, the former Chairperson, will remain a Board member.
• The company reported preliminary, unaudited cash, cash equivalents, and marketable securities of approximately $279 million as of December 31, 2025.
• A public follow-on offering in December 2025 raised approximately $105 million in gross proceeds, extending the expected cash runway into 2028.
• The cash runway is expected to fully fund the Stiff Person Syndrome (SPS) Biologics License Application (BLA) filing, commercial launch, and the Phase 3 generalized myasthenia gravis (gMG) trial.
• The first patient was enrolled in the Phase 3 registrational trial for miv-cel (KYV-101) in gMG in December 2025.
• The Investigational New Drug (IND) application for KYV-102, the company's whole blood rapid manufacturing process, was accepted by the U.S. FDA in January 2026, following its filing in December 2025.
• Kyverna intends to submit its first BLA for miv-cel in SPS in the first half of 2026, following positive topline data from the KYSA-8 registrational trial.

Sentiment

Score: 9

Explanation: The filing presents a highly positive outlook, highlighting significant clinical progress, a strengthened financial position, and a key strategic leadership appointment. The company is well-funded to advance its lead programs towards commercialization, with potential first-in-class therapies.

Positives

• Strengthened financial position with approximately $279 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Successful follow-on offering raised $105 million, extending the cash runway into 2028, expected to fully fund key programs.
• Anticipated Biologics License Application (BLA) submission for miv-cel in Stiff Person Syndrome (SPS) in the first half of 2026, following positive topline data.
• First patient enrolled in the registrational Phase 3 trial for miv-cel in generalized myasthenia gravis (gMG) in December 2025.
• U.S. FDA acceptance of the Investigational New Drug (IND) application for KYV-102 in January 2026.
• Appointment of Christi Shaw as Executive Chairperson brings significant CAR T commercialization experience, including her tenure as CEO of Kite (a Gilead Company).
• Potential for miv-cel to be the first FDA-approved therapy for SPS.

Risks

• Preliminary financial information is unaudited, based on current expectations, and subject to completion and adjustment.
• Forward-looking statements are subject to various important factors, including market conditions.
• Results from prior clinical trials, named-patient access activities, and preclinical studies may not necessarily be predictive of future results.
• The FDA or other regulatory agencies may require additional trials or studies to support the intended BLA submission.
• Uncertainties related to intellectual property rights.
• Other factors discussed in the Risk Factors section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Kyverna Therapeutics anticipates submitting its first Biologics License Application (BLA) for miv-cel in Stiff Person Syndrome (SPS) in the first half of 2026, with full registrational data expected in the same period. The company aims to achieve SPS launch readiness by year-end 2026. Enrollment for the Phase 3 generalized myasthenia gravis (gMG) trial will continue, with updated Phase 2 data expected in 2026. Further pipeline opportunities will be evaluated, including reporting Phase 2 investigator-initiated trial (IIT) data in rheumatoid arthritis, additional Phase 1 IIT data in multiple sclerosis, and Phase 1 data in lupus nephritis in 2026. The development strategy for KYV-102 will also be shared in 2026, and the company will explore miv-cel with no lymphodepletion or alternative regimens and outpatient administration. The recent follow-on offering is expected to extend the cash runway into 2028, fully funding the SPS BLA filing, commercial launch, and Phase 3 gMG trial.

Management Comments

• "Our strong execution in 2025 solidifies our leadership position in autoimmune CAR T with unprecedented clinical trial results for miv-celtiff person syndrome, followed by myasthenia gravis." Warner Biddle, CEO.
• "Looking ahead, we remain focused on preparing for our BLA filing with a clear regulatory path forward and the potential near-term launch in SPS, while executing on our Phase 3 gMG trial. These priorities are underpinned by our strong financial position, which will enable us to achieve key milestones across our late-stage programs." Warner Biddle, CEO.
• "In addition, we are pleased to share that Christi Shaw has been appointed as the Executive Chairperson of our Board. An industry veteran with a proven track record in CAR T, Christi further strengthens our CAR T leadership team experience, and her appointment comes at an important time as we actively prepare our organization to be launch-ready by the end of this year." Warner Biddle, CEO.
• "I’m excited to step into this expanded role as Kyverna advances towards delivering the first potential commercial CAR T-cell therapy in autoimmune disease." Christi Shaw, Executive Chairperson.
• "Kyverna has made strong progress demonstrating miv-cel’s potential in stiff person syndrome and myasthenia gravis. I look forward to building on this momentum with Warner and the team to bring the transformative promise of CAR T-cell therapy to patients with neuroimmunology conditions." Christi Shaw, Executive Chairperson.

Industry Context

Kyverna Therapeutics is positioning itself at the forefront of CAR T-cell therapy for autoimmune diseases, a rapidly evolving and high-potential therapeutic area. The appointment of Christi Shaw, a veteran with a proven track record in CAR T commercialization from her time as CEO of Kite (a Gilead Company), significantly bolsters Kyverna's leadership as it transitions towards potential commercialization. The company's lead candidate, miv-cel, is being advanced for Stiff Person Syndrome (SPS) with an anticipated BLA submission, aiming to be the first FDA-approved therapy for this condition, which would establish a significant market advantage. Progress in generalized myasthenia gravis (gMG) and other neuroimmunology conditions further diversifies its pipeline in a competitive but underserved market.

Comparison to Industry Standards

• The company highlights "unprecedented clinical trial results for miv-celtiff person syndrome" and "unprecedented interim Phase 2 data" for generalized myasthenia gravis, suggesting strong performance relative to existing or developing therapies in these indications.
• Christi Shaw's experience as CEO of Kite, where she led the company to become a "global leader in CAR T with multiple approved blood cancer indications in over 20 countries," sets a high benchmark for commercialization expertise and strategic leadership in the CAR T space. Her appointment indicates Kyverna's ambition to replicate such success in autoimmune diseases.
• The goal of delivering the "first potential commercial CAR T-cell therapy in autoimmune disease" and specifically the "first potential FDA-approved therapy for SPS" would represent a significant industry milestone, establishing Kyverna as a pioneer in this therapeutic area.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strengthened financial position, extended cash runway, significant clinical progress towards potential first-in-class therapies, and enhanced leadership with commercialization expertise.
• Patients (SPS, gMG, RA, MS, Lupus Nephritis): Potential for new, transformative CAR T-cell therapies to address unmet medical needs in severe autoimmune diseases.
• Employees: Potential for growth and expansion as the company moves towards commercialization, with a strengthened leadership team.
• Regulatory Authorities: The company is actively engaging with the FDA, with BLA submission planned and IND acceptance, indicating adherence to regulatory pathways.

Next Steps

• Submit Biologics License Application (BLA) for miv-cel in Stiff Person Syndrome (SPS) in the first half of 2026.
• Report full registrational data for SPS in the first half of 2026.
• Achieve SPS launch readiness by year-end 2026.
• Continue to advance enrollment for the Phase 3 portion of the KYSA-6 clinical trial for generalized myasthenia gravis (gMG).
• Report updated Phase 2 data from the gMG trial in 2026.
• Report Phase 2 investigator-initiated trial (IIT) data in rheumatoid arthritis in 2026.
• Report additional Phase 1 IIT data in multiple sclerosis in 2026.
• Report Phase 1 data in lupus nephritis in 2026.
• Share the development strategy for KYV-102 in 2026.
• Continue to explore miv-cel with no lymphodepletion (LD) or alternative LD regimen as well as outpatient administration.
• Present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026.

Key Dates

Recommendation

The filing indicates significant positive momentum for Kyverna Therapeutics. The company has achieved critical clinical milestones with positive data for miv-cel in SPS and gMG, positioning it for a potential first-in-class FDA approval in SPS. The successful $105 million follow-on offering substantially strengthens its financial position, extending the cash runway into 2028 and fully funding key development and commercialization efforts. The appointment of Christi Shaw, a highly experienced CAR T commercialization leader, further de-risks the upcoming launch phase. These factors collectively suggest a strong growth trajectory and significant upside potential for investors.

Keywords

Kyverna Therapeutics, KYTX, CAR T-cell therapy, Autoimmune diseases, Stiff Person Syndrome (SPS), Generalized Myasthenia Gravis (gMG), miv-cel (KYV-101), KYV-102, Biologics License Application (BLA), FDA, Clinical trial, Phase 3, Financial update, Cash runway, Christi Shaw, Executive Chairperson, Biopharmaceutical, Neuroimmunology